However, the potentially large target patient population, as well as the increased utilization and high drug costs, are a growing concern for many plan sponsors
However, these agents were linked to an increased likelihood of procedure discontinuation, presumably due to aggravated gastric retention [22]
The overexpression of CPT1A is often associated with tumor progression in several cancers such as breast, gastric, prostate, lymphoma, leukemia, ovarian, lung, and myeloma 20,21,22,23
nAMD is the more aggressive (wet) form of age-related macular degeneration
State-licensed pharmacies operating under Section 503A had until April 22, 2025, to cease production of compounded semaglutide that essentially copies the FDA-approved products